Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d5ac8bc979116652183ef40b40d45ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e1cca37900aa5edb0a262e16fcba73c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d4a1b10d12cb526d444e0d26da9a11b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_227417c5ecd8a61b829aac19a16c9095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1969421094b9bd3ad00f64302892c66a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8252c1e5751d579577e32c65f7a949c |
publicationDate |
2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2685553-T3 |
titleOfInvention |
IL-17 isoform antagonists and their uses |
abstract |
Composition that carries at least one IL-17 antagonist of an IL-17 isoform for use in the treatment of cancer, in which the IL-17 isoform is IL-17B, where the IL-17 antagonist is an antibody or an antigen-fixing antibody fragment against IL-17B or its IL-17RB receptor and where the treatment consists in increasing the effectiveness of a chemotherapeutic agent. |
priorityDate |
2012-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |